These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33237904)

  • 1. Blood pressure and bladder cancer risk in men by use of survival analysis and in interaction with NAT2 genotype, and by Mendelian randomization analysis.
    Teleka S; Hindy G; Drake I; Poveda A; Melander O; Liedberg F; Orho-Melander M; Stocks T
    PLoS One; 2020; 15(11):e0241711. PubMed ID: 33237904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three Swedish cohorts.
    Teleka S; Jochems SHJ; Häggström C; Wood AM; Järvholm B; Orho-Melander M; Liedberg F; Stocks T
    Cancer Med; 2021 Feb; 10(4):1431-1438. PubMed ID: 33455057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women.
    Teleka S; Häggström C; Nagel G; Bjørge T; Manjer J; Ulmer H; Liedberg F; Ghaderi S; Lang A; Jonsson H; Jahnson S; Orho-Melander M; Tretli S; Stattin P; Stocks T
    Int J Cancer; 2018 Dec; 143(12):3071-3082. PubMed ID: 29756343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction between smoking and bladder cancer genetic variants on urothelial cancer risk by disease aggressiveness.
    Teleka S; Jochems SHJ; Jirström K; Stocks T
    Cancer Med; 2022 Aug; 11(15):2896-2905. PubMed ID: 35285182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk.
    Elsalem L; Al Shatnawi A; A Alfaqih M; Alshoh A; Al Demour S; Al-Daghmin A; Halalsheh O; Kheirallah K; Ahram M
    Acta Biochim Pol; 2023 Aug; 70(3):575-582. PubMed ID: 37595067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. rs1495741 as a tag single nucleotide polymorphism of N-acetyltransferase 2 acetylator phenotype associates bladder cancer risk and interacts with smoking: A systematic review and meta-analysis.
    Ma C; Gu L; Yang M; Zhang Z; Zeng S; Song R; Xu C; Sun Y
    Medicine (Baltimore); 2016 Aug; 95(31):e4417. PubMed ID: 27495060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating interactions of polygenic risk scores and NAT2 genotypes with tobacco smoking in bladder cancer risk.
    Pradhan P; Jia G; Khankari NK; Zheng W
    Int J Cancer; 2024 Jan; 154(2):210-216. PubMed ID: 37728483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese.
    Inatomi H; Katoh T; Kawamoto T; Matsumoto T
    Int J Urol; 1999 Sep; 6(9):446-54. PubMed ID: 10510890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetyltransferase 2 polymorphism is associated with bladder cancer risk: An updated meta-analysis based on 54 case-control studies.
    Song Y; Qi X; Liu X
    Gene; 2020 Oct; 757():144924. PubMed ID: 32622992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
    Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
    Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. White Blood Cells and Blood Pressure: A Mendelian Randomization Study.
    Siedlinski M; Jozefczuk E; Xu X; Teumer A; Evangelou E; Schnabel RB; Welsh P; Maffia P; Erdmann J; Tomaszewski M; Caulfield MJ; Sattar N; Holmes MV; Guzik TJ
    Circulation; 2020 Apr; 141(16):1307-1317. PubMed ID: 32148083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
    Stern MC; Johnson LR; Bell DA; Taylor JA
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
    Koutros S; Kiemeney LA; Pal Choudhury P; Milne RL; Lopez de Maturana E; Ye Y; Joseph V; Florez-Vargas O; Dyrskjøt L; Figueroa J; Dutta D; Giles GG; Hildebrandt MAT; Offit K; Kogevinas M; Weiderpass E; McCullough ML; Freedman ND; Albanes D; Kooperberg C; Cortessis VK; Karagas MR; Johnson A; Schwenn MR; Baris D; Furberg H; Bajorin DF; Cussenot O; Cancel-Tassin G; Benhamou S; Kraft P; Porru S; Carta A; Bishop T; Southey MC; Matullo G; Fletcher T; Kumar R; Taylor JA; Lamy P; Prip F; Kalisz M; Weinstein SJ; Hengstler JG; Selinski S; Harland M; Teo M; Kiltie AE; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Schned A; Lenz P; Riboli E; Brennan P; Tjønneland A; Otto T; Ovsiannikov D; Volkert F; Vermeulen SH; Aben KK; Galesloot TE; Turman C; De Vivo I; Giovannucci E; Hunter DJ; Hohensee C; Hunt R; Patel AV; Huang WY; Thorleifsson G; Gago-Dominguez M; Amiano P; Golka K; Stern MC; ; Yan W; Liu J; Li SA; Katta S; Hutchinson A; Hicks B; Wheeler WA; Purdue MP; McGlynn KA; Kitahara CM; Haiman CA; Greene MH; Rafnar T; Chatterjee N; Chanock SJ; Wu X; Real FX; Silverman DT; Garcia-Closas M; Stefansson K; Prokunina-Olsson L; Malats N; Rothman N
    Eur Urol; 2023 Jul; 84(1):127-137. PubMed ID: 37210288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
    Wu H; Wang X; Zhang L; Mo N; Lv Z
    Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort.
    Fontana L; Delort L; Joumard L; Rabiau N; Bosviel R; Satih S; Guy L; Boiteux JP; Bignon YJ; Chamoux A; Bernard-Gallon DJ
    Anticancer Res; 2009 May; 29(5):1631-5. PubMed ID: 19443378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population.
    Hosen MB; Islam J; Salam MA; Islam MF; Hawlader MZ; Kabir Y
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):78-84. PubMed ID: 25376209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
    Cascorbi I; Roots I; Brockmöller J
    Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.